{"organizations": [], "uuid": "5e6dc4fdc5a1e192ec52a6f6ff74756adad7b7d9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/11/business-wire-rocket-pharmaceuticals-reports-first-quarter-2018-financial-results-and-operational-highlights.html", "country": "US", "domain_rank": 767, "title": "Rocket Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.951, "site_type": "news", "published": "2018-05-11T15:00:00.000+03:00", "replies_count": 0, "uuid": "5e6dc4fdc5a1e192ec52a6f6ff74756adad7b7d9"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/11/business-wire-rocket-pharmaceuticals-reports-first-quarter-2018-financial-results-and-operational-highlights.html", "ord_in_thread": 0, "title": "Rocket Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights", "locations": [], "entities": {"persons": [{"name": "gaurav shah", "sentiment": "none"}], "locations": [{"name": "new york", "sentiment": "none"}], "organizations": [{"name": "gene therapy programs potentially in clinic", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "pkd", "sentiment": "none"}, {"name": "rocket pharmaceuticals, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Four Gene Therapy Programs Potentially in Clinic in 2019 with Clinical Data from up to Two Programs\nRegulatory Submissions on Schedule for LAD-I, PKD and AAV Programs Over the Next 12 Months\nDevelopment of a Long-term Sustainable Growth Company Leveraging a Multi-Platform Approach\nNEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today reported financial results for the quarter ended March 31, 2018, and provided an update on the Company’s recent achievements, as well as upcoming milestones.\n“2018 is off to a great start for Rocket. During the first quarter, we continued to make excellent progress advancing our pipeline of lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy programs towards key value inflection points. We look forward to presenting updated patient data from the Fanconi Anemia program later this month, and to disclosing our AAV-based gene therapy program by the end of the year,” said Gaurav Shah, M.D., Chief Executive Officer and President of Rocket. “We remain on track for multiple regulatory filings across our pipeline over the next 12 months. As a result, there is the potential for four programs to be in the clinic in 2019, with clinical data for up to two programs.”\nDr. Shah continued, “While near-term milestones are certainly important, Rocket's long-term strategy is based on a sustainable and integrated multi-platform approach. We remain focused on our mission of continued innovation to deliver best-in-class curative cell and gene therapies to patients living with devastating diseases.”\nAnticipated Milestones Over the Next 12 -18 Months\nFanconi Anemia (FA): Updated patient data from the ongoing Phase 1/2 study of RP-L102 conducted with CIEMAT is expected over the next 12 months. The next update will be provided at the American Society of Gene and Cell Therapy’s (ASGCT) 21 st Annual Meeting in Chicago. The oral presentation is scheduled during the Presidential Symposium on Friday, May 18, 2018, at 2:45 p.m. Central Time. Leukocyte Adhesion Deficiency-I (LAD-I): An Investigational Medicinal Product Dossier (IMPD) is expected to be filed in the fourth quarter of 2018. Clinical data is expected over the next 12-18 months. Pyruvate Kinase Deficiency (PKD): An IMPD application is expected to be filed in early 2019. Infantile Malignant Osteopetrosis (IMO): Preclinical studies continue to advance in support of filing a first-in-human clinical study. AAV: Disclosure of the disease indication and preclinical data is planned for the second half of 2018.\nUpcoming Conferences\nBank of America Merrill Lynch Health Care Conference 2018 . Rocket is scheduled to present on Tuesday, May 15, at 9:20 a.m. Pacific Time. UBS Global Healthcare Conference. Rocket is scheduled to present on Wednesday, May 23, at 9:30 a.m. Eastern Time. Jefferies Global Healthcare Conference. Rocket is scheduled to present on Thursday, June 7, at 2:00 p.m. Eastern Time.\nFirst Quarter 2018 Financial Results\nCash position. Cash, cash equivalents and short-term investments as of March 31, 2018, were $182.7 million, which includes a $52.0 million fully convertible debenture which expires in 2021. R&D expenses. Research and development expenses were $5.7 million for the quarter ended March 31, 2018, compared to $2.3 million for the quarter ended March 31, 2017. G&A expenses . General and administrative expenses were $8.7 million for the quarter ended March 31, 2018, compared to $0.6 million for the quarter ended March 31, 2017. The increase in G&A expenses was primarily due to one-time merger related expenses of $5.3 million. Net loss . Net loss was $15.3 million or $(0.42) per share (basic and diluted) for the quarter ended March 31, 2018, compared to $2.7 million or $(0.39) per share (basic and diluted) for the quarter ended March 31, 2017. Shares outstanding . Approximately 39.4 million shares of common stock were outstanding as of March 31, 2018.\nFinancial Guidance\nCash position. Based on its current operating plan, Rocket expects its cash, cash equivalents and short-term investments as of March 31, 2018, will be sufficient to run its operations into 2020.\nAbout Rocket Pharmaceuticals, Inc.\nRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit www.rocketpharma.com .\nCautionary Statement Regarding Forward-Looking Statements\nVarious statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the safety, effectiveness and timing of products that Rocket may develop, including in collaboration with academic partners, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO), and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these , which often include words such as \"believe\", \"expect\", \"anticipate\", \"intend\", \"plan\", \"will give\", \"estimate\", \"seek\", \"will\", \"may\", \"suggest\" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these as a result of various important factors, including, without limitation, Rocket’s ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the preclinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket’s product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket’s product candidates, Rocket’s ability to manage operating expenses, Rocket’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2017. Accordingly, you should not place undue reliance on these . All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any , whether as a result of new information, future events or otherwise.\nSelected Financial Information Operating Results: (amounts in thousands, except share and per share data) Three Months Ended March 31, 2018 2017 Revenue $ - $ - Operating expenses: Research and development 5,743 2,285 General and administrative 8,662 585 Total operating expenses 14,405 2,870 Loss from operations (14,405 ) (2,870 ) Research and development incentives 186 192 Interest expense (1,427 ) - Interest income 288 - Other income 15 - Net loss $ (15,343 ) $ (2,678 ) Net loss per share attributable to common shareholders - basic and diluted $ (0.42 ) $ (0.39 ) Weighted-average common shares outstanding - basic and diluted 36,137,120 6,795,627 Selected Balance Sheet Information (amounts in thousands) March 31, December 31, 2018 2017 Cash, cash equivalents and short-term investments 182,697 18,142 Total assets 217,165 20,147 Total liabilities 47,019 4,628 Total shareholders' equity 170,146 15,519\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180511005223/en/\nClaudine Prowse, Ph.D.\nSVP Corporate Development and IRO\nRocket Pharmaceuticals, Inc.\nThe Alexandria Center for Life Science\n430 East 29 Street, Suite 1040\nNew York, NY 10016\ncp@rocketpharma.com\nSource: Rocket Pharmaceuticals, Inc.", "external_links": ["https://www.businesswire.com/news/home/20180511005223/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.rocketpharma.com&esheet=51804455&newsitemid=20180511005223&lan=en-US&anchor=www.rocketpharma.com&index=1&md5=352c25cda462976322366b009080e4b6"], "published": "2018-05-11T15:00:00.000+03:00", "crawled": "2018-05-11T16:17:52.014+03:00", "highlightTitle": ""}